Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation

N Ketterer1, G Salles, M Raba

  • 1Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.

Blood
|May 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolated third cranial nerve involvement as the presenting feature of diffuse large B-cell lymphoma.

Revue neurologique·2021
Same author

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib.

BMC pharmacology & toxicology·2020
Same author

Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium.

Blood cancer journal·2020
Same author

Tissue-nonspecific alkaline phosphatase is an anti-inflammatory nucleotidase.

Bone·2020
Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate?

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Reinfusing over 15 million CD34(+) cells/kg in peripheral blood progenitor cell transplantation significantly speeds up neutrophil and platelet recovery. This high dose reduces transfusion needs and may improve patient quality of life after chemotherapy for blood cancers.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Oncology

Background:

  • Optimal CD34(+) cell reinfusion doses for peripheral blood progenitor cell (PBPC) transplantation post-chemotherapy remain unclear.
  • Hematopoietic reconstitution varies significantly based on infused CD34(+) cell counts.

Purpose of the Study:

  • To determine the optimal number of CD34(+) cells for reinfusion in PBPC transplantation.
  • To analyze the impact of CD34(+) cell dose on hematologic recovery and patient outcomes in lymphoproliferative diseases.

Main Methods:

  • Retrospective analysis of 168 PBPC transplantations in patients with lymphoproliferative diseases.
  • Categorization into low (≤2.5 x 10^6/kg), intermediate, and high (>15 x 10^6/kg) CD34(+) cell groups.
  • Comparison of neutrophil and platelet recovery times, transfusion requirements, and hospital stay across groups.

Related Experiment Videos

Main Results:

  • Low CD34(+) cell dose group showed significantly delayed neutrophil and platelet recovery (P < .0001).
  • High CD34(+) cell dose group had significantly shorter engraftment times for both neutrophils (P = .003) and platelets (P < .0001) compared to the intermediate group.
  • High CD34(+) cell dose correlated with reduced platelet transfusion needs (P = .002) and shorter hospital stays (P = .01).

Conclusions:

  • Reinfusion of >15 x 10^6 CD34(+) cells/kg significantly accelerates hematopoietic reconstitution after high-dose chemotherapy for lymphoproliferative diseases.
  • Higher CD34(+) cell doses reduce platelet requirements and may improve patient quality of life.
  • CD34(+) cell dose is a critical factor influencing recovery post-PBPC transplantation.